Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US81663L2007
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00XDHY5P9
WGS
GeneDx Holdings Corp
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $GRLZ
NAME
GeneDx Holdings Corp
ISIN
US81663L2007
TICKER
WGS
MIC
XNAS
REUTERS
WGS.OQ
BLOOMBERG
WGS US
Thu, 23.07.2026       GeneDx
US81663L2007

NEW YORK, July 22, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plai...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.07.2026       GeneDx
US81663L2007

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 22, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit agains...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.07.2026       GeneDx
US81663L2007

The Red Flags: What GeneDx Insiders Allegedly Knew About Fabric Genomics' Failures Before Shareholders Learned the $31.2 Million TruthNEW YORK, July 22, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP announces that a securities class action has been filed against GeneDx Holdings Corp. (NASDAQ: WGS)....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.07.2026       GeneDx
US81663L2007

SAN FRANCISCO, July 21, 2026 /PRNewswire/ -- Hagens Berman (HBSS), a national leader in securities litigation, is actively investigating claims in a securities class action lawsuit against GeneDx Holdings (NASDAQ: WGS) and its executives, alleging defendants misled investors about the Fabric Genomics acquisition and synergy potential....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.07.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - July 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plaintiff deadline.SO WHAT: If you purchased GeneDx comm...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.07.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - July 21, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.07.2026       GeneDx
US81663L2007

NEW YORK, July 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GeneDx Holdings Corp. (NASDAQ: WGS). Shareholders who purchased shares of WGS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.07.2026       GeneDx
US81663L2007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wils...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.07.2026       GeneDx
US81663L2007

San Diego, California--(Newsfile Corp. - July 21, 2026) - Robbins Geller Rudman & Dowd LLP announces that purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026, both dates inclusive (the "Class Period"), have until Monday, August 3, 2026 to seek appointment as lead plaintiff of the GeneDx class ac...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.07.2026       GeneDx
US81663L2007

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 20, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit agains...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 20.07.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - July 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plaintiff deadline.SO WHAT: If you purchased GeneDx comm...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.07.2026       GeneDx
US81663L2007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wils...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Sun, 19.07.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - July 19, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Sun, 19.07.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - July 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plaintiff deadline.SO WHAT: If you purchased GeneDx comm...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.07.2026       GeneDx
US81663L2007

Did you buy WGS securities between April 16, 2025, and May 4, 2026?Affected WGS Investor SummaryWho: GeneDx Holdings Corp. (NASDAQ: WGS)What: Securities fraud class action lawsuit filedClass Period: April 16, 2025 through May 4, 2026Deadline to Seek Lead Plaintiff Status: August 3, 2026Key Lawsuit Allegations: Material misstatements and/or omissio...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.07.2026       GeneDx
US81663L2007

NEW YORK, July 17, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plai...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.07.2026       GeneDx
US81663L2007

NEW YORK CITY and NEW ORLEANS, July 17, 2026 /PRNewswire/ -- - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have untilAugust 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against GeneDx Holdings C...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.07.2026       GeneDx
US81663L2007

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 17, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit agains...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.07.2026       GeneDx
US81663L2007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wils...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.07.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - July 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plaintiff deadline.SO WHAT: If you purchased GeneDx comm...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 16.07.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the second quarter of 2026 after the market closes on Monday, August 3, 2026. Management will host a conference call that day to discuss second quarter 2026 financial and operating...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.07.2026       GeneDx
US81663L2007

Important Information Regarding Section 20(a) Individual Liability Claims Against GeneDx CEO and CFO for Alleged $33.42 Per-Share Investor Losses Tied to reimbursement weakness and underperformance of Fabric GenomicsNEW YORK, July 16, 2026 /PRNewswire/ -- SueWallSt alerts investors in GeneDx Holdings Corp. (NASDAQ: WGS) that two senior executives...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.07.2026       GeneDx
US81663L2007

NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against GeneDx Holdings Corp. ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are e...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.07.2026       GeneDx
US81663L2007

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026. GeneDx Holdings Corp is a genomics company that provides genetic testing services for diagnosing pediatric and rare diseases. For mo...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.07.2026       GeneDx
US81663L2007

SAN FRANCISCO, July 16, 2026 /PRNewswire/ -- Hagens Berman (HBSS), a national leader in securities litigation, is actively investigating claims in a securities class action lawsuit against GeneDx Holdings (NASDAQ: WGS) and its executives, alleging defendants misled investors about the Fabric Genomics acquisition and synergy potential....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.07.2026       GeneDx
US81663L2007

SAN DIEGO, July 15, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026, all dates inclusive (the "Class Period"), have until Monday, August 3, 2026 to seek appointment as lead plaintiff of the GeneDx class act...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.07.2026       GeneDx
US81663L2007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wils...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.07.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - July 15, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.07.2026       GeneDx
US81663L2007

Notice to Pension Funds, Asset Managers, and Fiduciaries Holding GeneDx Holdings Corp. (WGS) Shares: $33.42 Per-Share Decline Raises Fiduciary Evaluation ObligationsNEW YORK, July 15, 2026 /PRNewswire/ -- Institutional investors holding positions in GeneDx Holdings Corp. (NASDAQ: WGS) during the period from April 16, 2025 through May 4, 2026 may w...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.07.2026       GeneDx
US81663L2007

SAN FRANCISCO, July 15, 2026 /PRNewswire/ -- Hagens Berman (HBSS), a national leader in securities litigation, is actively investigating claims in a securities class action lawsuit against GeneDx Holdings (NASDAQ: WGS) and its executives, alleging defendants misled investors about the Fabric Genomics acquisition and synergy potential....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.07.2026       GeneDx
US81663L2007

NEW YORK, July 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GeneDx Holdings Corp. (NASDAQ: WGS). Shareholders who purchased shares of WGS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.07.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - July 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plaintiff deadline.SO WHAT: If you purchased GeneDx comm...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.07.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - July 13, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.07.2026       GeneDx
US81663L2007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wils...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.07.2026       GeneDx
US81663L2007

LOS ANGELES, July 13, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholder...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.07.2026       GeneDx
US81663L2007

LOS ANGELES, July 13, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.07.2026       GeneDx
US81663L2007

NEW YORK, July 12, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plain...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.07.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - July 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plaintiff deadline.SO WHAT: If you purchased GeneDx comm...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Sat, 11.07.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - July 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plaintiff deadline.SO WHAT: If you purchased GeneDx comm...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Sat, 11.07.2026       GeneDx
US81663L2007

NEW ORLEANS, July 10, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against GeneDx Holdings Corp. (NasdaqGS: WGS), if they purchased or otherwise acquired the Company's shares between April 16,...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.07.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - July 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plaintiff deadline.SO WHAT: If you purchased GeneDx comm...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.07.2026       GeneDx
US81663L2007

SAN DIEGO, July 10, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), have until Monday, August 3, 2026 to seek appointment as lead plaintiff of the GeneDx class action lawsuit.  Captioned Ba...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.07.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - July 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plaintiff deadline.SO WHAT: If you purchased GeneDx commo...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.07.2026       GeneDx
US81663L2007

San Diego, California--(Newsfile Corp. - July 9, 2026) - Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026. GeneDx Holdings Corp is a genomics company that provides genetic testing servi...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.07.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - July 9, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations o...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.07.2026       GeneDx
US81663L2007

Levi & Korsinsky, LLP highlights the contrast between GeneDx Holdings Corp.'s (NASDAQ: WGS) promises to investors and the actual results of its Fabric Genomics acquisition. Shareholders who purchased WGS securities between April 16, 2025 and May 4, 2026 and suffered losses may be entitled to compensation. Find out if you can recover your inves...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.07.2026       GeneDx
US81663L2007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wils...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.07.2026       GeneDx
US81663L2007

SAN FRANCISCO, July 9, 2026 /PRNewswire/ -- Hagens Berman (HBSS), a national leader in securities litigation, is actively investigating claims in a securities class action lawsuit against GeneDx Holdings (NASDAQ: WGS) and its executives, alleging defendants misled investors about the Fabric Genomics acquisition and synergy potential....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.07.2026       GeneDx
US81663L2007

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 8, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.07.2026       GeneDx
US81663L2007

SAN FRANCISCO, July 7, 2026 /PRNewswire/ -- Hagens Berman (HBSS), a national leader in securities litigation, is actively investigating claims in a securities class action lawsuit against GeneDx Holdings (NASDAQ: WGS) and its executives, alleging defendants misled investors about the Fabric Genomics acquisition and synergy potential....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink